Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Verlängerungsstudie für Patienten, die zuvor an Studien mit Pelabresib teilgenommen haben

6. November 2026 aktualisiert von: Novartis Pharmaceuticals

Eine offene, multizentrische Verlängerungsstudie für Patienten, die zuvor an Studien mit Pelabresib teilgenommen haben

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The study will collect and monitor ongoing efficacy information with regard to disease and survival status, as well as safety information with regard to AEs, including SAEs and AEs of special interest (AESI).

Patients are eligible to continue pelabresib treatment as long as the regimen is tolerated, and the patient does not meet any of the discontinuation criteria.

Patients who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study.

There will be an eligibility check period of up to 28 days for this extension study. Patients who fulfill the inclusion and exclusion criteria are eligible for the study. After the patient willingly provides consent, eligibility will be assessed by the investigator and treatment with pelabresib can be started at the same dose and dosing schedule that was applied in the parent study in the last cycle prior to EOT unless there is need for dose adjustment due to toxicity.

A patient is considered to have completed the study after completion of all visits as defined in the Schedule of Assessments (SoA) as per protocol, including the Safety Follow-up visit and Survival Follow-up.

The Safety Follow-up period is the interval between the EOT visit and the scheduled Safety Follow-up visit, which should occur 30 days (±3 days) after the last dose of pelabresib. For patients who switch from investigational pelabresib to commercial pelabresib treatment, the Safety Follow-up period is the time from the last dose of investigational pelabresib until the first dose of commercial pelabresib. The treatment start date with commercial pelabresib will be considered the date of "early Safety Follow-up termination." All patients will be followed for AEs and SAEs for 30 days (±3 days) following the last dose of pelabresib on the extension study or until the initiation of a new anticancer therapy, whichever occurs first.

Reasonable efforts should be made to have the patient return for the Safety Follow-up visit and review any AEs that may occur during this period. If the patient cannot return to the site for the Safety Follow-up visit, then the patient should be contacted by telephone for assessment of AEs.

The end of study will occur when all parent studies have been closed with no further patients expected to be enrolled into the extension study, and all patients are either discontinued or study treatment becomes commercially available and reimbursed, or an alternate access program becomes available, whichever comes first. Prior to study completion, all patients should.have completed the Safety Follow-up visit or have been designated as lost to follow-up, died, or have withdrawn consent, whichever comes first. The sponsor reserves the right to close a study site or terminate the study at any time for any reason at the sole discretion of the sponsor.

Studientyp

Interventionell

Einschreibung (Geschätzt)

50

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Antwerp, Belgien, 2030
        • Rekrutierung
        • Novartis Investigative Site
      • Bruges, Belgien, 8000
        • Rekrutierung
        • Novartis Investigative Site
      • Novara, Italien, 28100
        • Rekrutierung
        • Novartis Investigative Site
    • FI
      • Florence, FI, Italien, 50134
        • Rekrutierung
        • Novartis Investigative Site
    • VA
      • Varese, VA, Italien, 21100
        • Rekrutierung
        • Novartis Investigative Site
      • Amsterdam, Niederlande, 1081
        • Rekrutierung
        • Novartis Investigative Site
    • California
      • Los Angeles, California, Vereinigte Staaten, 90095
        • Rekrutierung
        • University of California LA
        • Hauptermittler:
          • Gary Schiller
        • Kontakt:
    • Florida
      • Jacksonville, Florida, Vereinigte Staaten, 32224
        • Rekrutierung
        • Mayo Clinic Jacksonville
        • Hauptermittler:
          • Candido Rivera
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Rekrutierung
        • Northwestern University
        • Hauptermittler:
          • Brady L Stein
        • Kontakt:
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48109
        • Rekrutierung
        • Uni Of Michigan Health System
        • Hauptermittler:
          • Moshe Talpaz
        • Kontakt:
    • New York
      • New York, New York, Vereinigte Staaten, 10021
        • Rekrutierung
        • New York Presbyterian Hospital
        • Hauptermittler:
          • Joseph Scandura
        • Kontakt:
      • New York, New York, Vereinigte Staaten, 10029-6574
        • Rekrutierung
        • Mt Sinai Medical Center
        • Hauptermittler:
          • Marina Kremyanskaya
        • Kontakt:
      • Cardiff, Vereinigtes Königreich, CF14 4XW
        • Rekrutierung
        • Novartis Investigative Site
      • Glasgow, Vereinigtes Königreich, G12 0YN
        • Rekrutierung
        • Novartis Investigative Site
      • London, Vereinigtes Königreich, SE1 7EH
        • Rekrutierung
        • Novartis Investigative Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Able to provide signed informed consent, agreeing to all protocol and ICF requirements.

  • At least 18 years old and legally able to consent in the study's jurisdiction.

  • Previously enrolled and currently receiving pelabresib in combination with ruxolitinib or ruxolitinib alone in a parent study.

  • Demonstrating clinical benefit from pelabresib and/or ruxolitinib, as judged by the investigator.

  • Willing and able to follow all study visits, treatments, and procedures.

  • Agree to avoid pregnancy or fathering children:

    • Men: Must use highly effective contraception (≥99% effective) and avoid sperm donation from eligibility check through 94 days post-treatment.
    • Women of childbearing potential (WOCBP): Must test negative for pregnancy at eligibility, use highly effective contraception through 184 days post-treatment, undergo regular pregnancy testing, and avoid breastfeeding and oocyte donation during this period.
    • Women not of childbearing potential (surgically sterile or postmenopausal ≥12 months without other cause) are eligible.

Note: Women with amenorrhea due to chemo/radiotherapy are considered WOCBP and must use contraception.

Additional Inclusion Criteria control (placebo + ruxolitinib) group requiring pelabresib combination treatment:

  • On a stable dose of ruxolitinib for ≥8 weeks

  • Has adequate bone marrow and organ function as defined by the following local laboratory values:

    • ANC ≥ 1 × 10^9/L in the absence of growth factors for the previous 4 weeks
    • Platelet count ≥ 75 × 10^9/L in the absence of growth factors or platelet transfusions during previous 4 weeks
    • Peripheral blood blast count < 5%
    • AST and/or ALT ≤ 2.5 × ULN of the local reference interval (≤ 5 × if the elevation can be ascribed to hepatic MF involvement, e.g., presence of hepatomegaly)
    • Serum direct bilirubin < 2.0 × ULN of the local reference interval
    • Calculated or measured CrCl of ≥ 45 mL/min
  • Does not have any other concurrent medical condition that in the opinion of the investigator could compromise participation in the study

Exclusion Criteria:

  • Legally institutionalized or under judicial protection.
  • Enrolled in another interventional clinical trial (excluding the parent study).
  • History of hypersensitivity to pelabresib, its excipients, or similar drugs.
  • Significant gastrointestinal issues (e.g., active IBD, unresolved nausea/vomiting/diarrhea > Grade 1) that may affect drug absorption.
  • Any medical condition deemed unsuitable by the investigator.
  • Uncontrolled illness or condition that may compromise safety or protocol compliance.
  • Received systemic anticancer or investigational treatment (excluding parent study drug or hormonal therapy) within 2 weeks or 5 half-lives before first dose. (Hydroxyurea/anagrelide allowed up to 24 hours prior.)
  • Received hematopoietic growth factors or androgenic steroids within 4 weeks before first dose.
  • Used strong CYP3A4 inhibitors/inducers (e.g., St. John's wort) within 2 weeks before first dose. Use during treatment is prohibited.
  • Received immunosuppressive agents with systemic activity (>10 mg QD prednisone or equivalent) less than 4 weeks before the first dose of study drug in the extension study. Participants who received topical, nasal, intra-articular, inhaled, and other forms of corticosteroids without systemic activity are eligible
  • Received a live vaccination within 30 days prior to the first dose of study drug in the extension study, except for COVID-19 vaccination
  • Female participants who are pregnant, breastfeeding, or not using required contraception.
  • Male participants who do not agree to use contraception or refrain from sperm donation as specified.
  • Unwilling or unable to comply with the study protocol.

Additional Exclusion Criterion for participants receiving ruxolitinib only treatment

• Local access to commercially available and reimbursed ruxolitinib.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Pelabresib and/or ruxolitinib

Participants who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study.

Additionally, the MANIFEST-2 (NCT04603495) control group (i.e., treated with placebo + ruxolitinib) patients, will be offered pelabresib combination treatment at the time of enrollment if the investigator sees any potential benefit of adding pelabresib to ruxolitinib.

Small molecule inhibitor of bromodomain and extraterminal (BET) protein

Andere Namen:
  • CPI-0610

Small molecule selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2.

Andere Namen:
  • Jakavi™/Jakafi™

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Treatment-emergent adverse events (TEAEs) and serious TEAEs
Zeitfenster: 5 years

To evaluate long-term safety in patients who are receiving pelabresib

5 years
Survival Follow-up
Zeitfenster: 5 years

Survival Follow-up consists of Survival and Leukemia-Free Survival Follow-up. All participants in the extension study will be followed up for Survival, while participants with hematological malignancies will be followed up for Survival and Leukemia-Free Survival.

5 years
Duration of Response (DoR)
Zeitfenster: 5 years

DOR defined as the time from the date of first response to the date of confirmed disease progression

5 years
Progression-free survival (PFS)
Zeitfenster: 5 years

PFS defined as the time from first dose to confirmed disease progression or death, whichever occurs first.

5 years
Leukemia-free survival (LFS)
Zeitfenster: 5 years

LFS defined as the time from first dose to the date of leukemic transformation or death, whichever occurs first.

5 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

13. August 2024

Primärer Abschluss (Geschätzt)

31. Dezember 2029

Studienabschluss (Geschätzt)

31. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

2. Mai 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Mai 2024

Zuerst gepostet (Tatsächlich)

6. Mai 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CDAK539A12001B
  • CNST0610C210 (Andere Kennung: Constellation Pharmaceuticals)
  • 2023-508950-24-00 (Registrierungskennung: EU CT Number)
  • 2023 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .